TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39167533

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous PTH (1-34) infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (10 patients with primary hyperparathyroidism and 10 healthy volunteers)
Number of subjects: 10
Study: 39167741

Group type: EXPERIMENTAL
Intervention: Personalized chemotherapy based on tumor marker decline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39167748

Group type: COMPARATOR
Intervention: Any migraine
Number of subjects: 39312

Group type: COMPARATOR
Intervention: Migraine with aura
Number of subjects: 39312

Group type: COMPARATOR
Intervention: Migraine without aura
Number of subjects: 39312

Group type: COMPARATOR
Intervention: History of migraine
Number of subjects: 39312

Group type: COMPARATOR
Intervention: Migraine frequency less than monthly
Number of subjects: 39312
Study: 39167764

Group type: EXPERIMENTAL
Intervention: Proactive systematic hemophilia carrier screening
Number of subjects: 900
Study: 39167766

Group type: EXPERIMENTAL
Intervention: Gilteritinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39167788

Group type: EXPERIMENTAL
Intervention: Short-Term Diesel Exhaust Exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 39167806

Group type: EXPERIMENTAL
Intervention: Child azithromycin group
Number of subjects: 382586

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 382586

Group type: EXPERIMENTAL
Intervention: Infant azithromycin group
Number of subjects: 382586
Study: 39167807

Group type: EXPERIMENTAL
Intervention: Belzutifan (120 mg orally once daily)
Number of subjects: 746

Group type: COMPARATOR
Intervention: Everolimus (10 mg orally once daily)
Number of subjects: 746
Study: 39168179

Group type: EXPERIMENTAL
Intervention: Growth failure defined as a weight z-score of -1.8 or below at 36 weeks PMA
Number of subjects: 5393

Group type: EXPERIMENTAL
Intervention: Growth faltering defined as a weight z-score decline of 1.1 or greater from birth to 36 weeks PMA
Number of subjects: 5393

Group type: EXPERIMENTAL
Intervention: Length z-score less than -1 at 36 weeks PMA
Number of subjects: 5393

Group type: EXPERIMENTAL
Intervention: Head circumference z-score decline of 2.43 or greater from birth to 36 weeks PMA
Number of subjects: 5393

Group type: EXPERIMENTAL
Intervention: Standard definitions for risk detection of cognitive impairment
Number of subjects: 5393

Group type: EXPERIMENTAL
Intervention: Monitoring length and head circumference z-scores
Number of subjects: 5393
Study: 39168180

Group type: EXPERIMENTAL
Intervention: Obstructive Sleep Apnea (OSA)
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Central Sleep Apnea (CSA)
Number of subjects: 656

Group type: COMPARATOR
Intervention: Control (no to mild sleep apnea)
Number of subjects: 656
Study: 39168356

Group type: EXPERIMENTAL
Intervention: SABR
Number of subjects: 90

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 90
Study: 39168360

Group type: EXPERIMENTAL
Intervention: Condoliase (1.25 units)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 352
Study: 39168564

Group type: EXPERIMENTAL
Intervention: Olpasiran 75 mg Q12W
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Olpasiran 225 mg Q12W
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study: 39168591

Group type: EXPERIMENTAL
Intervention: Continuous rhythm monitoring
Number of subjects: 349
Study: 39168901

Group type: EXPERIMENTAL
Intervention: Sitravatinib (MGCD516)
Number of subjects: 48
Study: 39168946

Group type: EXPERIMENTAL
Intervention: PwPOMS
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25
Study: 39168966

Group type: EXPERIMENTAL
Intervention: Atezolizumab and Bevacizumab (AtzBev)
Number of subjects: 0
Study: 39169033

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study: 39169058

Group type: EXPERIMENTAL
Intervention: Immune killer cells (IKC) infusion weekly for 24 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Immune killer cells (IKC) infusion
Number of subjects: 26
Study: 39169095

Group type: EXPERIMENTAL
Intervention: Invisalign SmileView simulation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Invisalign treatment with upper and lower aligners (average treatment time of 18 ± 6 months)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Qualitative assessment of smile parameters
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Quantitative assessment of maxillary inter canine width
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Qualitative assessment of lip line
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Qualitative assessment of most posterior tooth display, smile arc, and lower incisor exposure
Number of subjects: 24
Study: 39169297

Group type: EXPERIMENTAL
Intervention: Incremental high power radiofrequency ablation (RFA) with multi-electrodes
Number of subjects: 110
Study: 39169298

Group type: EXPERIMENTAL
Intervention: 5-day postoperative antibiotic therapy (piperacillin/tazobactam)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antibiotic prophylaxis
Number of subjects: 0
Study: 39169349

Group type: EXPERIMENTAL
Intervention: Surgical treatment group using the Dialogue Support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-surgical treatment group using the Dialogue Support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Retrospective matched control group (no Dialogue Support)
Number of subjects: 0
Study: 39169350

Group type: EXPERIMENTAL
Intervention: Immobilisation for 0 weeks (Group A)
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Immobilisation for 2 weeks (Group B)
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Immobilisation for 4 weeks (Group C)
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Immobilisation for 6 weeks (Group D)
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C, D)
Number of subjects: 1088
Study: 39169353

Group type: EXPERIMENTAL
Intervention: Soymilk (500 mL daily, 22 g soy protein, 17.2 g or 6.9 g/250 mL added sugars)
Number of subjects: 504
Study: 39169395

Group type: EXPERIMENTAL
Intervention: Surgical PIP joint denervation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Patient education and exercise program
Number of subjects: 90
Study: 39169663

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy (P-ESWL) followed by endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 2071
Study: 39169699

Group type: EXPERIMENTAL
Intervention: PEERS® program (treatment group, n=10)
Number of subjects: 21
Study: 39169827

Group type: COMPARATOR
Intervention: DS-7011a (anti-TLR7 monoclonal antibody) administered intravenously (IV) and subcutaneously (SC) in a 6:2 ratio against placebo.
Number of subjects: 80

Group type: COMPARATOR
Intervention: DS-7011a (anti-TLR7 monoclonal antibody) administered IV and SC.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 80
Study: 39169834

Group type: EXPERIMENTAL
Intervention: Chiropractic care and Tai Chi training
Number of subjects: 0
Study: 39170110

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg esketamine + PCEA
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg esketamine + PCIA
Number of subjects: 118

Group type: COMPARATOR
Intervention: saline + PCEA
Number of subjects: 118

Group type: COMPARATOR
Intervention: saline + PCIA
Number of subjects: 118
Study: 39170271

Group type: EXPERIMENTAL
Intervention: HAr® 0.1 % (Ribohyal®)
Number of subjects: 16

Group type: COMPARATOR
Intervention: HA 0.1 % eye drops
Number of subjects: 16
Study: 39170685

Group type: EXPERIMENTAL
Intervention: iVES-bPFMT (20-min iVES and 20-min bPFMT sessions, twice per week, for 3 months)
Number of subjects: 21

Group type: COMPARATOR
Intervention: TOT implantation (trans-obturator tape surgery)
Number of subjects: 21
Study: 39170956

Group type: EXPERIMENTAL
Intervention: Clopidogrel intervention
Number of subjects: 61
Study: 39171074

Group type: EXPERIMENTAL
Intervention: Combination of nonpharmacological interventions including a daily dose of both investigational products and dietary counseling on increasing dietary fiber.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Daily dose of both investigational drugs only.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fish oil investigational product and placebo.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control arm with no intervention.
Number of subjects: 100
Study: 39171125

Group type: EXPERIMENTAL
Intervention: Lung cancer patients in 2012
Number of subjects: 119785

Group type: EXPERIMENTAL
Intervention: Lung cancer patients in 2020
Number of subjects: 119785

Group type: EXPERIMENTAL
Intervention: Lung cancer patients diagnosed in 2012
Number of subjects: 119785

Group type: EXPERIMENTAL
Intervention: Lung cancer patients diagnosed in 2020
Number of subjects: 119785

Group type: EXPERIMENTAL
Intervention: Lung adenocarcinoma cases in 2012
Number of subjects: 119785

Group type: EXPERIMENTAL
Intervention: Lung adenocarcinoma cases in 2020
Number of subjects: 119785

Group type: EXPERIMENTAL
Intervention: Lung squamous cell carcinoma cases in 2012
Number of subjects: 119785

Group type: EXPERIMENTAL
Intervention: Lung squamous cell carcinoma cases in 2020
Number of subjects: 119785
Study: 39171394

Group type: EXPERIMENTAL
Intervention: Intravenous acetazolamide
Number of subjects: 519

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Hypochloremia
Number of subjects: 519
Study: 39171416

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Valera Health smartphone application
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: ACT + Valera Health smartphone application
Number of subjects: 280

Group type: COMPARATOR
Intervention: Treatment as Usual
Number of subjects: 280
Study: 39171616

Group type: EXPERIMENTAL
Intervention: Hybrid fixation (circular fixation combined with insertion of percutaneous screws)
Number of subjects: 948

Group type: COMPARATOR
Intervention: Single-plating ORIF
Number of subjects: 948

Group type: COMPARATOR
Intervention: Bone substitute
Number of subjects: 948
Study: 39171624

Group type: EXPERIMENTAL
Intervention: Prednisone therapy for two months
Number of subjects: 4670

Group type: EXPERIMENTAL
Intervention: Prolonged prednisone therapy beyond two to three months
Number of subjects: 4670

Group type: EXPERIMENTAL
Intervention: Daily prednisone therapy at the onset of infection
Number of subjects: 4670

Group type: EXPERIMENTAL
Intervention: Lower induction doses or shorter durations of prednisone therapy
Number of subjects: 4670
Study: 39171639

Group type: COMPARATOR
Intervention: Education programmes compared to routine care alone
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Education programmes for people receiving dialysis who have diabetes
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Education programmes for people with diabetes and moderately increased albuminuria (A2)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Education programme
Number of subjects: 840

Group type: COMPARATOR
Intervention: Education programme plus multidisciplinary, co-ordinated care compared to routine care
Number of subjects: 840
Study: 39171864

Group type: EXPERIMENTAL
Intervention: ABP 959
Number of subjects: 42

Group type: COMPARATOR
Intervention: Eculizumab RP
Number of subjects: 42
Study: 39171906

Group type: EXPERIMENTAL
Intervention: Conventional GCs (cortisone acetate or hydrocortisone)
Number of subjects: 86

Group type: COMPARATOR
Intervention: DR-HC
Number of subjects: 86
Study: 39172032

Group type: EXPERIMENTAL
Intervention: Lumbosacral spinal cord stimulation (SCS) via transcutaneous stimulation or epidural stimulation
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: User Experience Questionnaire (UEQ)
Number of subjects: 6
Study: 39172240

Group type: EXPERIMENTAL
Intervention: Flexible visitation (12 hours/day)
Number of subjects: 519

Group type: COMPARATOR
Intervention: Restrictive visitation (median 1.5 hours/day)
Number of subjects: 519
Study: 39172246

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CTA)
Number of subjects: 64
Study: 39172363

Group type: EXPERIMENTAL
Intervention: Mind wandering
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39172356

Group type: EXPERIMENTAL
Intervention: COVID+ Black participants
Number of subjects: 4113

Group type: EXPERIMENTAL
Intervention: COVID+ females
Number of subjects: 4113

Group type: EXPERIMENTAL
Intervention: Transgender/non-binary/other gender participants
Number of subjects: 4113
Study: 39172389

Group type: EXPERIMENTAL
Intervention: HPV vaccination intention
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Promotion targeting adolescents and their social environment
Number of subjects: 649
Study: 39172402

Group type: EXPERIMENTAL
Intervention: FLOW program implementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Successful sites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Struggling sites
Number of subjects: 0
Study: 39172428

Group type: EXPERIMENTAL
Intervention: $333/month unconditional cash transfer
Number of subjects: 1000

Group type: COMPARATOR
Intervention: $20/month unconditional cash transfer
Number of subjects: 1000
Study: 39172446

Group type: EXPERIMENTAL
Intervention: Elinzanetant 120 mg once daily for 26 weeks
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo for 12 weeks followed by elinzanetant 120 mg for 14 weeks
Number of subjects: 399
Study: 39172463

Group type: EXPERIMENTAL
Intervention: Early adenotonsillectomy (eAT)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Watchful waiting with supportive care (WWSC)
Number of subjects: 375
Study: 39172479

Group type: EXPERIMENTAL
Intervention: Olaparib, 300 mg by mouth twice daily until PSA doubling, clinical or radiographic progression, or unacceptable toxic effects.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 51
Study: 39172534

Group type: EXPERIMENTAL
Intervention: MORE-VR (Mindfulness-Oriented Recovery Enhancement)
Number of subjects: 23
Study: 39172627

Group type: EXPERIMENTAL
Intervention: Pimodivir + SoC (oseltamivir)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo + SoC (oseltamivir)
Number of subjects: 0
Study: 39172632

Group type: EXPERIMENTAL
Intervention: Fecal microbiota, live-jslm (REBYOTA®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39172711

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 2160

Group type: EXPERIMENTAL
Intervention: Bariatric surgery with remission of type 2 diabetes (T2D)
Number of subjects: 2160
Study: 39172725

Group type: EXPERIMENTAL
Intervention: Laparoscopic pancreatoduodenectomy
Number of subjects: 252

Group type: COMPARATOR
Intervention: Open pancreatoduodenectomy
Number of subjects: 252
Study: 39172730

Group type: EXPERIMENTAL
Intervention: ARX517 (a site-specific stable PSMA-targeted antibody-drug conjugate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ARX517
Number of subjects: 0
Study: 39172743

Group type: EXPERIMENTAL
Intervention: D-positive RHD genotyped units transfused
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: D-positive transfusions
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Unexpected anti-C and anti-E
Number of subjects: 5
Study: 39172760

Group type: EXPERIMENTAL
Intervention: Teclistamab 1.5 mg/kg weekly
Number of subjects: 40
Study: 39172815

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39173075

Group type: EXPERIMENTAL
Intervention: TAK-003 vaccine (two doses administered 3 months apart)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAK-003 vaccine (baseline vaccination scenario)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAK-003 vaccine (extreme high scenario)
Number of subjects: 0
Study: 39173088

Group type: COMPARATOR
Intervention: CEE-alone (0.625 mg daily)
Number of subjects: 26747

Group type: COMPARATOR
Intervention: CEE plus MPA (0.625 mg CEE plus 2.5 mg MPA daily)
Number of subjects: 26747
Study: 39173098

Group type: EXPERIMENTAL
Intervention: pembrolizumab plus chemotherapy
Number of subjects: 492

Group type: COMPARATOR
Intervention: placebo plus chemotherapy
Number of subjects: 492
Study: 39173142

Group type: EXPERIMENTAL
Intervention: Personalized normative feedback intervention
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control condition with resources for seeking care
Number of subjects: 800
Study: 39173175

Group type: EXPERIMENTAL
Intervention: Lumacaftor/Ivacaftor treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39173182

Group type: EXPERIMENTAL
Intervention: Hyperandrogenic PCOS
Number of subjects: 1376

Group type: COMPARATOR
Intervention: Nonhyperandrogenic PCOS
Number of subjects: 1376
Study: 39173229

Group type: EXPERIMENTAL
Intervention: Plinabulin (30 mg/m²), nivolumab (1 mg/kg), ipilimumab (3 mg/kg)
Number of subjects: 39
Study: 39173549

Group type: EXPERIMENTAL
Intervention: Allied primary healthcare intervention over 12 months
Number of subjects: 1451

Group type: EXPERIMENTAL
Intervention: Allied primary healthcare intervention between 6 and 12 months
Number of subjects: 1451

Group type: EXPERIMENTAL
Intervention: Total allied healthcare costs
Number of subjects: 1451
Study: 39173550

Group type: EXPERIMENTAL
Intervention: Prism Adaptation (PA)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Neck Muscle Vibration (NMV)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Prism Adaptation + Neck Muscle Vibration (PA+NMV)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study: 39173560

Group type: EXPERIMENTAL
Intervention: Self-reports (SR)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Pill counts (PC)
Number of subjects: 107

Group type: COMPARATOR
Intervention: DBS tenofovir concentrations
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Adherence (≥90%)
Number of subjects: 107
Study: 39173604

Group type: EXPERIMENTAL
Intervention: CKD stage 5 on dialysis
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 105

Group type: COMPARATOR
Intervention: CKD stage 1 and 2
Number of subjects: 105
Study: 39173603

Group type: EXPERIMENTAL
Intervention: Web-based genetic education (WGE)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 63
Study: 39173703

Group type: EXPERIMENTAL
Intervention: Sufficient preconception 25(OH)D levels in females
Number of subjects: 2370

Group type: EXPERIMENTAL
Intervention: Sufficient preconception 25(OH)D levels in females with normal BMI
Number of subjects: 2370

Group type: EXPERIMENTAL
Intervention: Sufficient preconception 25(OH)D levels in males with normal BMI
Number of subjects: 2370

Group type: EXPERIMENTAL
Intervention: Sufficient preconception 25(OH)D levels in females with obesity
Number of subjects: 2370

Group type: EXPERIMENTAL
Intervention: Both partners with sufficient preconception 25(OH)D levels
Number of subjects: 2370

Group type: EXPERIMENTAL
Intervention: Preconception vitamin D status and bioavailability
Number of subjects: 2370

Group type: COMPARATOR
Intervention: Pregnancy loss
Number of subjects: 2370

Group type: COMPARATOR
Intervention: Semen quality
Number of subjects: 2370
Study: 39173781

Group type: EXPERIMENTAL
Intervention: EUS-guided fiducial marker placement using a preloaded 22-gauge EchoTip Ultra Fiducial Needle
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: EUS-guided fiducial marker placement
Number of subjects: 33
Study: 39173973

Group type: EXPERIMENTAL
Intervention: Higher Healthy Eating Index for habitual diet
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Fecal SCFA abundance
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Diet and microbiome features
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Potatoes
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Thiamine biosynthesis pathway
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Thiamine
Number of subjects: 359
Study: 39174002

Group type: EXPERIMENTAL
Intervention: Early point-of-care ultrasound (POCUS) cardiac standstill
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: End-tidal CO2 (ETCO2) value ≤37 mmHg
Number of subjects: 293
Study: 39174056

Group type: EXPERIMENTAL
Intervention: 4F-PCC (1500 or 2000 international units)
Number of subjects: 410

Group type: COMPARATOR
Intervention: FP (3 or 4 units depending on body weight)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: 4F-PCC and FP
Number of subjects: 410
Study: 39174068

Group type: EXPERIMENTAL
Intervention: Dolutegravir-based ART
Number of subjects: 0
Study: 39174285

Group type: EXPERIMENTAL
Intervention: Primary care treatment for LTBI
Number of subjects: 362

Group type: COMPARATOR
Intervention: Secondary care treatment for LTBI
Number of subjects: 362
Study: 39174297

Group type: EXPERIMENTAL
Intervention: Referral pathway and interactions with primary care physicians (PCPs)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Journey undertaken by families from initially trivialising symptoms to a growing sense of urgency
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Perception gap between families' growing disquiet and first medical interventions
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Lack of guidance from physicians prompting parents to initiate action
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Various elements of the care pathway influencing diagnosis experience
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Psychosocial consequences of delayed diagnosis in JIA
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Implementation of views and experiences in training programmes and guidelines for PCPs
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Development of online supports integrating medical knowledge and family testimonials
Number of subjects: 19
Study: 39174449

Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) plus progressive muscle relaxation (PMR) intervention
Number of subjects: 20
Study: 39174542

Group type: EXPERIMENTAL
Intervention: Sintilimab (anti-PD1 antibody), stereotactic body radiotherapy (SBRT), and granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Sintilimab, SBRT, and GM-CSF
Number of subjects: 49
Study: 39174547

Group type: EXPERIMENTAL
Intervention: Palbociclib-tamoxifen
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo-tamoxifen
Number of subjects: 184
Study: 39174857

Group type: EXPERIMENTAL
Intervention: Delayed-release form containing 1.9 mg melatonin, 10 mg zinc, and 200 mg lemon balm extract
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Delayed-release form
Number of subjects: 12